Risk of Using Sodium Valproate in Female Patients

posted Feb 15, 2017, 7:37 PM by Izam Ezri Mohd Zakaria
26th January 2017 (Circular NO. SP PPUM: 34/2017):
The National Pharmaceutical Regulatory Agency (NPRA) has issued a guide on the use of Valproate in female patients due to the risk of abnormal pregnancy outcomes.
Please click here to read the "Guide for Healthcare Profesionals- Medicines Related to Valproate: Updates on the Risk of Abnormal Pregnancy Outcomes".